Novo Nordisk A/S $NVO Position Decreased by CIBC Asset Management Inc

CIBC Asset Management Inc reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,026 shares of the company’s stock after selling 55,857 shares during the quarter. CIBC Asset Management Inc’s holdings in Novo Nordisk A/S were worth $1,888,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. True Wealth Design LLC boosted its stake in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares in the last quarter. NewSquare Capital LLC boosted its position in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter worth about $37,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth about $39,000. Finally, Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after buying an additional 186 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 4.2%

NVO stock opened at $60.28 on Thursday. The company has a 50 day moving average of $52.97 and a two-hundred day moving average of $54.54. The company has a market cap of $269.14 billion, a price-to-earnings ratio of 17.52 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. BMO Capital Markets set a $57.00 target price on Novo Nordisk A/S in a report on Monday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $57.79.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Product momentum: rapid uptake of oral Wegovy, recent UK approval, an Amazon partnership and delays for a Lilly rival have supported demand and helped drive a rally into earnings. Article Title
• Positive Sentiment: Market-share push: Reuters data shows Novo spent nearly $500M on U.S. advertising for Wegovy/Ozempic through Sept 2025 — an aggressive spend to defend and grow share versus rivals. This supports near-term sales momentum but increases near-term cash outlays. Article Title
• Positive Sentiment: Short interest dropped ~13% in January, reducing immediate short-pressure and indicating fewer bearish positions ahead of the report. (January short-interest data)
• Neutral Sentiment: Earnings event: NVO is scheduled to report quarterly results this week — the report and management commentary will be the primary near-term catalyst. Article Title
• Neutral Sentiment: Analyst / media commentary: Some outlets are touting Novo as a rebound pick after last year’s selloff, which can attract longer-term buyers but has limited impact on near-term price moves. Article Title
• Negative Sentiment: Guidance risk: A Seeking Alpha preview argues management may give conservative 2026 guidance to manage expectations, which could trigger a near-term negative sentiment swing even if fundamentals remain strong. Article Title
• Negative Sentiment: Competition & execution risk: Analyst pieces warn the obesity/GLP‑1 field is getting crowded (e.g., Viking, Lilly) which raises long‑term execution and margin pressures and keeps upside more uncertain. Article Title

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.